MTOR and melanoma: Correspondingly, recent research has corroborated that selective inhibition of these pathways(mTOR and ERBB) presents a promising therapeutic avenue for melanoma variants that exhibit resistance to PD-1 monoclonal antibodies, which are critical in the disease’s advancement (70, 71).